Alterity participates in JP Morgan healthcare conference
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Dr David Stamler Appointed CEO
- Form F-3
- New commercial opportunity for PBT2
- Alterity presents at Finance News Network
- Prospectus filed pursuant to SEC Rule 424(b)(3)
Later from Alterity Therapeutics
- Michael J Fox grant for Parkinsons research on ATH434
- Alterity to present at Global Life Science Conference
- ATH434 protects brain cells and improves motor function
- EU Regulatory Guidance for ATH434 Phase 2 Clinical Trial
- New US patent targeting major neurodegenerative diseases
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics